# Study of ATX-01 in Participants With DM1

> **NCT06300307** · PHASE1,PHASE2 · RECRUITING · sponsor: **ARTHEx Biotech S.L.** · enrollment: 56 (estimated)

## Conditions studied

- Myotonic Dystrophy 1

## Interventions

- **DRUG:** ATX-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06300307
- **Lead sponsor:** ARTHEx Biotech S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06300307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06300307, "Study of ATX-01 in Participants With DM1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06300307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*